This Obesity Drug Preserves 50% More Muscle Than GLP-1s Alone (And It Could Be Approved by September 30th)

Myostatin inhibitors have been the whispered promise of side-effect-free muscle growth for nearly two decades.

Within the next month, the FDA faces two critical decisions that could finally transform this long-awaited dream into reality—or crush it entirely.

Dr. Alex, a leading voice in evidence-based fitness science, recently broke down everything researchers and fitness enthusiasts need to know about this emerging drug class, including one crucial manufacturing detail that determines who gets access, when, and at what cost.

The stakes couldn’t be higher, especially for the millions currently taking GLP-1 medications like Wegovy or Ozempic.

The Myostatin Backstory: Twenty Years in the Making

Myostatin functions as the body’s built-in brake on muscle growth. Scientists first identified this protein in 1997 by genetically knocking it out in mice, accidentally creating extraordinarily muscular rodents.

Similar mutations were later observed in cattle and whippets, producing animals with dramatically increased muscle mass. The visual results were undeniable—but translating that into human therapies proved frustratingly elusive.

The core problem? American pharmaceutical economics.

Every potential drug requires an “indication”—a well-defined pathological condition that the therapy reliably improves. Simply helping healthy people build more muscle doesn’t fit that regulatory model, regardless of consumer demand.

Why Progress Stalled for Two Decades

Rare diseases like muscular dystrophy, spinal muscular atrophy, and FOP (where soft tissue slowly ossifies into bone) seemed like logical targets. But these markets remain tiny.

Even with orphan drug designation incentives from the FDA, pharmaceutical executives showed limited enthusiasm for drugs that might only reach 50 patients annually.

Then came the GLP-1 revolution.

Millions of Americans now take semaglutide (Wegovy), tirzepatide (Mounjaro), or similar medications for obesity and diabetes. This represents the largest potential market in pharmaceutical history—and it comes with a significant problem that myostatin inhibitors might solve.

The GLP-1 Muscle Loss Problem

Approximately 30% of weight loss from GLP-1 medications comes from muscle tissue when used as monotherapy without resistance training. This applies across the entire class—semaglutide, tirzepatide, retatrutide—all produce similar results.

Losing muscle isn’t just a cosmetic concern. Maintaining muscle mass is essential for long-term metabolic health, functional capacity, and quality of life.

Enter apitegromab, the new frontrunner in myostatin inhibition that wasn’t even mentioned in Dr. Alex’s previous coverage 15 months ago.

How Apitegromab Works Differently

Myostatin doesn’t start as active myostatin. Cells produce it as a larger precursor protein requiring two enzymatic “cuts” before activation.

The first cut separates a wrapper from the business end, but the wrapper remains attached, keeping myostatin inactive. A second enzyme family then cuts the wrapper itself, finally releasing active myostatin.

Previous failed drug candidates targeted finished myostatin—which sounds logical until you realize finished myostatin shares 90% identity with a cousin protein called GDF11. Blocking the shared receptor hits everything that docks there, causing unwanted side effects.

Apitegromab takes a smarter approach. It binds the precursor wrapper and jams the second enzymatic scissors, preventing myostatin release entirely while avoiding collateral damage to GDF11, activin, and related proteins.

The Clinical Evidence: Finally, Success

September 2024 marked a watershed moment—apitegromab became responsible for the first successful Phase 3 trial in this entire drug class.

The trial enrolled 188 patients with spinal muscular atrophy. Those receiving apitegromab showed statistically significant improvements on motor function scales.

More importantly, the safety profile was exceptional:

• Zero treatment-related serious adverse events
• Zero patient withdrawals
• Zero deaths

Then came the June 2024 EMBRACE trial—a Phase 2 study that could pave the pathway to mass-market adoption.

The EMBRACE Trial: Preserving Muscle During Weight Loss

Researchers enrolled 102 overweight or obese adults, giving half apitegromab plus tirzepatide for 24 weeks, while the control group received tirzepatide plus placebo.

The apitegromab group lost 1.9 kilograms less lean mass compared to controls—meaning they only lost half the muscle they would have otherwise. Total weight loss remained identical between groups.

Read that again: same total weight loss, but more muscle preserved. That means substantially more fat was lost—achieving legitimate body recomposition without any resistance training whatsoever.

The Regulatory Rollercoaster

Scholar Rock, the company behind apitegromab, submitted their spinal muscular atrophy data to the FDA and received an initial rejection—not because the drug failed, but because their manufacturing facility in Bloomington, Indiana failed basic FDA quality inspections.

A second inspection at the same plant also failed. Scholar Rock now relies on a second manufacturing location currently undergoing FDA inspection.

The formal decision deadline is September 30th, though approval could come any day before that. This timeline applies to the spinal muscular atrophy indication specifically—not for obesity combined with GLP-1 use.

Other Myostatin Inhibitors in Development

Bimagrumab: The Most Powerful Option

Owned by Eli Lilly (also Indiana-based), bimagrumab blocks the receptor where myostatin and numerous other proteins bind. It remains the strongest drug in this class by a significant margin.

A major trial published in March 2024 enrolled 507 adults across nine study arms. The high-dose bimagrumab plus semaglutide group achieved remarkable results:

• 22.1% total body weight loss at 72 weeks (versus 15.7% for semaglutide alone)
• 92% of weight loss came from fat
• Only 8% of weight loss was muscle (compared to the typical 30% with GLP-1s alone)

These results are unprecedented for medication without testosterone or resistance training.

However, side effects proved substantial. Muscle spasms affected 46-74% of patients depending on dosage, alongside acne and diarrhea.

Oh, Jesus, you ran metformin and clen at the same time? How do you have the runs and vibrate at the same time?

Rumors circulated that cardiac toxicity concerns killed the program, but that’s not entirely accurate. Bimagrumab monotherapy raised LDL cholesterol approximately 17%—not ideal, but semaglutide canceled this effect in combination therapy.

Lilly hasn’t shelved bimagrumab. An ongoing trial combining bimagrumab with tirzepatide remains active.

Trevogrumab: Regeneron’s Myostatin-Specific Antibody

Full 26-week data landed in September 2024. Patients taking semaglutide alone experienced a 6.5% drop in whole-body lean mass.

Adding trevogrumab reduced that loss to just 3.3%—meaning roughly half the muscle loss was prevented and proportionally more fat was eliminated. Results closely mirror apitegromab’s performance.

Garetosmab: The Activin A Blocker with Safety Concerns

Also owned by Regeneron, garetosmab’s safety profile raised eyebrows. During the first FOP study, five deaths occurred during the open-label phase.

Investigators deemed them unlikely related but couldn’t rule out the connection entirely. Additionally, 50% of patients experienced nosebleeds (versus 17% on placebo), alongside skin and soft tissue infections.

Regeneron closed the trial, reduced the dose, implemented additional safety monitoring, and restarted. The revised approach worked—new bone lesions dropped 94%.

Garetosmab now has priority review status with a decision expected later this month. However, the obesity trial combining semaglutide, trevogrumab, and garetosmab—which produced exceptional body composition results—also recorded two deaths with no established link, and significant patient withdrawals due to side effects.

The Emerging Pattern: Efficacy vs. Tolerability

A clear trend emerges across this drug class: the more of the pathway you block, the better it works and the worse patients feel.

Apitegromab appears safest but achieves roughly half the effect of bimagrumab, the most powerful option.

So, the pattern for this whole class boils down to this. The more of this pathway you block, the better it works and the worse you feel.

Could This Create Side-Effect-Free Muscle Growth?

Consider bimagrumab monotherapy—without any GLP-1 and without resistance training mentioned in protocols. Patients still experienced decreased fat and increased lean mass simultaneously.

That represents body recomposition in an IV bag, something never previously achieved pharmaceutically.

Anabolic steroids build muscle but ignore fat. GLP-1s strip fat but sacrifice muscle. Myostatin inhibitors are the first class that moves both dials in favorable directions simultaneously.

For performance enhancement enthusiasts, these drugs work through a completely separate mechanism from the androgen receptor. Theoretically, stacking them with anabolic steroids should produce additive rather than redundant effects—potentially pushing the ceiling for lean tissue accrual beyond anything anabolic steroids alone have achieved.

The Troubling Absence of Strength Data

Despite improving lean mass retention, myostatin inhibitors have never been conclusively shown to make anyone stronger.

When bimagrumab was first studied for inclusion body myositis (a rare muscle-wasting disease), lean mass increased but patients’ walking distance remained unchanged. The entire program was subsequently canceled.

In sarcopenia trials, lean mass jumped 7% compared to placebo—but overall function showed no improvement. After hip fracture, patients gained pounds of lean mass without recovering any faster.

Here’s a startling fact: across every obesity trial in this class—bimagrumab, trevogrumab, apitegromab—zero reported strength or functional endpoints alongside body composition measurements.

The FDA’s Position on Lean Mass

The FDA issued draft guidance in January 2025 stating that losing lean mass during weight loss has not historically been treated as problematic.

Any drug anchoring labeled benefits on body composition must demonstrate that patients feel better, function better, or live longer.

This creates a massive approval hurdle for drugs like apitegromab, where total weight loss in the apitegromab-plus-tirzepatide group equaled the tirzepatide-alone control group.

Without demonstrating symptomatic, functional, or lifespan benefits, the FDA literally doesn’t care about lean mass preservation or DEXA scan improvements. They only care about total weight reduction.

The Monoclonal Antibody Problem Nobody’s Discussing

Every drug in this class is a monoclonal antibody—and that classification changes everything about accessibility and cost.

Monoclonal antibodies are massive. Peptides like BPC-157 typically contain 40 amino acids or fewer. Apitegromab contains over 1,300 amino acids—roughly 90 times larger than typical peptides.

Once a molecule exceeds that 40-amino-acid threshold, the FDA classifies it as a “biologic,” radically altering regulatory pathways.

What This Means for Access and Cost

1. Compounding is impossible. There is absolutely no legal pathway for compounding pharmacies to produce these drugs in the United States. Period.

The FDA explicitly states biological products aren’t eligible for compounding exemptions. There’s no shortage list workaround like what occurred with GLP-1s, and no bulk list nomination pathway.

2. Extended exclusivity. Regular drugs or peptides receive 5 years of market exclusivity. Biologics get 12 years, and competitors cannot even file copycat applications for the first 4 years.

An affordable biosimilar version won’t reach the market until approximately 2040.

3. Complex manufacturing requirements. Peptides involve straightforward chemistry—machines can synthesize them reliably.

Antibodies require living engineered cell lines, bioreactors, and purification systems costing more than most hospitals. Gray-market monoclonal antibody production essentially doesn’t exist.

Buyer Beware: The Counterfeit Risk

If you encounter apitegromab for sale online, run. As of now, there’s a 0% chance any such product is legitimate.

The risk profile differs dramatically from peptides. When peptides degrade, they typically just stop working. When antibodies are manufactured poorly or mishandled, proteins clump—and clumped proteins can trigger immune systems to build antibodies against the drug itself.

Apitegromab’s immunogenicity in trials was negligible, but that involved properly manufactured product under strict quality control.

While nobody has definitively proven counterfeit myostatin antibodies cause autoimmune disease, it represents a real theoretical risk absent with simpler peptide structures.

The Realistic Timeline for Mass Access

In the immediate term, this represents a significant win for rare disease patients. Within eight weeks, apitegromab could receive approval for spinal muscular atrophy and garetosmab for adult FOP.

For affected families, that’s life-changing. It will also validate manufacturing processes and familiarize prescribers with the drug class—both critical for future expansion.

But for obesity and mass-market adoption? Nobody is close.

Not a single Phase 3 trial is currently running in this class for weight loss indications. Dr. Alex previously predicted nothing before 2028 would be shocking—but 2029 or 2030 now seems far more realistic.

Scholar Rock has publicly acknowledged they lack resources to sponsor an obesity trial independently. They’re actively seeking partnership to fund such research.

Who Will Actually Get Access?

When obesity approval eventually arrives, the indication almost certainly won’t read “everybody on a GLP-1.”

Instead, expect restriction to:

• Older adults with low baseline muscle mass
• Documented sarcopenia diagnoses
• Rapid, aggressive weight loss scenarios

These represent the only cases where insurance companies might agree to cover a second expensive injectable medication.

No Early Access This Time

For fitness enthusiasts hoping to access myostatin inhibitors today, there’s no pathway. The early-access situation that occurred with retatrutide simply cannot happen with monoclonal antibodies because synthesis complexity makes gray-market production essentially impossible.

So, you know, just stick with the things that work. Lifting, sleeping, protein, tren.

The promise of side-effect-free muscle drugs remains tantalizingly close yet frustratingly distant. Manufacturing realities, regulatory hurdles, and economic factors all conspire to keep these compounds out of reach for the general population—at least for now.

Progress continues, but patience remains essential. The myostatin inhibitor revolution may be coming, just not as quickly as the internet hype suggests.